Get to know our clinical trials
Clinical trial of pyrtobrutinib (LOXO-305) compared to ibrutinib in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (BRUIN-CLL-314).
THE OBJECTIVES OF THIS CLINICAL TRIAL ARE AS FOLLOWS: - TO DETERMINE THE RESPONSE OF CLL/LLCP PATIENTS TO TREATMENT WITH PYRTOBRUTINIB (GROUP A) COMPARED TO IBRUTINIB (GROUP B). - DETERMINE THE DURATION OF BENEFICIAL EFFECTS OF TREATMENT WITH THE STUDY DRUGS (INCLUDING HOW LONG PATIENTS LIVE). - DETERMINE SAFETY AND TOLERABILITY IN GROUP A AND GROUP B. - DETERMINE HOW PATIENTS IN GROUP A ARE DOING COMPARED TO THOSE IN GROUP B.
Technical Summary
- PHASE III, OPEN-LABEL, RANDOMIZED, OPEN-LABEL STUDY OF PYRTOBRUTINIB (LOXO-305) COMPARED TO IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL CELL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314).
- Code EudraCT: 2021-003206-41
- Protocol number: LOXO-BTK-20030
- Promoter: Loxo Oncology, Inc.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.